Prostate-Specific Antigen Screening and Prostate Cancer Mortality: An Emulation of Target Trials in US Medicare.
Xabier Garcia de AlbenizJohn HsuRuth B EtzioniJune Maylin ChanJoy ShiBarbra A DickermanMiguel A HernánPublished in: JCO clinical cancer informatics (2024)
Our estimates suggest that under conventional statistical criteria, annual PSA screening for 8 years is highly compatible with reductions of PC mortality from four to one fewer PC deaths per 1,000 screened men age 67-74 years. As with any study using real-world data, the estimates could be affected by residual confounding.